Prospective single arm open clinical trial to study the efficacy of Yakridari Loha in the manangement of Pandu in Udara with special reference to Anemia in Liver Cirrhosis.

Current Clinical Trial is Titled as " Prospective single arm open clinical trial to study the efficacy of Yakridari loha in the management of pandu in udara with special reference to Anemia in Liver cirrhosis".

The trial drug used in this clinical study is Yakridari loha which will be given in the dose 500mg twice a day for 21 days.

The sample size of this study will be 30.

It is single arm prospective open clinical trial.

The patient will be  selected from opd and Ipd of our concerned institute.

the purpose of the trial is to assess the efficacy of Yakridari loha.

The Null Hypothesis for this trial is -Yakridari Loha 500mg orally twice a day for 21 days is not effective in the management of Pandu in Udara with special reference to Anemia in liver Cirrhosis.

The Alternate Hypothesis for this trial is -Yakridari Loha 500mg orally twice a day for 21 days is  effective in the management of Pandu in Udara with special reference to Anemia in liver Cirrhosis.

Observation and Results -

Above clinical research study in 30 patients of Pandu in Udara w.s.r. to  Anemia in Liver Cirrhosis with Yakridari Loha shows following results

In subjective criteria it is evident that total no of patients shows

59.68% relief in Panduta parameter, 52.28% relief in Hridspandana, 57.69% relief in Shwaskashtata, 71.67% relief in Daurbalyata, 68.75% relief in Aruchi, 68% relief in Agnimandya, 75.68% relief in Pindikodwestana and 30.30% relief was seen in Pada shotha.

Overall 60.52% relief is observed in subjective criteria.

In objective criteria, for Hb%, statistically high significant difference was seen in values between the time intervals. For total bilirubin and SGPT also, statistically significant difference was seen in values between the time intervals. Hence, Hb%, T.B. and SGPT showed statistically significant result. Whereas, in TLC, ESR, SGOT, Blood urea, Serum creatinine, Urine RBCs and Urine Albumin parameters, there was statistically no significant difference seen in values between the time interval. Therefore, these parameters showed statistically not significant result.

Tab Yakridari Loha showed marked improvement (i.e.76%-100%) in 12(40%) patients of Pandu in Udara with special reference to anemia in liver cirrhosis. It showed Moderate improvement (i.e. 51%-75%) in 12 (40%) patients and gave mild improvement (i.e. 26%-50%) in 2(6.67%) patients. 3 (10%) patients showed no improvemet (i.e. 0%-25%) to Tab Yakridari Loha.

Conclusion -

Based on P value, it can be concluded that the Null Hypothesis is rejected and the Alternative Hypothesis can be retained, indicating that Yakridari Loha is effective in the management of Pandu In Udara w.s.r. to Anemia in Liver Cirrhosis.

There is no noticeable adverse effects of the drug observed during the treatment period. Yakridari Loha is clinically safe and effective preparation that does not have any side effects in managing Pandu in udara when combined with proper Pathya and Aahar-Vihar.